Rahika 150 mg Tablet 12's

Rahika 150 mg Tablet is used to treat advanced or metastatic non-small cell lung cancer (NSCLC). Lung cancer is a type of cancer that begins when cells in the lungs grow abnormally. These cells do not perform normal lung functions and fail to form healthy lung tissue. In this condition, lung cells grow uncontrollably and, if not identified early, may spread to other body parts (metastatic). NSCLC is a category of lung cancer that happens when cells that form the lining of the lung start growing uncontrollably.

Rahika 150 mg Tablet contains 'Capmatinib,' which belongs to a class of medications called 'kinase inhibitors.' It blocks the action of an abnormal protein (the mesenchymal-epithelial transition [MET] gene) that helps cancer cells in the lungs grow and multiply, thereby preventing cancer from spreading.

Rahika 150 mg Tablet should be taken precisely as prescribed by your doctor. Continue taking Rahika 150 mg Tablet for the duration specified, based on your medical condition. In some cases, Rahika 150 mg Tablet may cause common side effects such as nausea, vomiting, coughing, difficulty breathing, fatigue, weakness, loss of appetite, muscle or bone pain, swelling in the hands or feet, or changes in specific blood tests. These side effects are generally mild and do not need medical attention. However, you are advised to consult your doctor if these side effects persist or worsen.

Before starting treatment with Rahika 150 mg Tablet , inform your doctor if you are allergic to any of its ingredients or other medications. Rahika 150 mg Tablet may increase your sensitivity to sunlight, so limiting exposure to sunlight and using sunscreen and protective clothing outdoors is essential. Do not use Rahika 150 mg Tablet if you are pregnant or planning pregnancy, as it may harm an unborn baby. Inform your doctor of your medical history, particularly if you have liver disease, lung problems, or pancreatitis (inflammation of the pancreas), before starting Rahika 150 mg Tablet .

Rahika 150 mg Tablet is a targeted cancer medicine used to treat advanced or metastatic non-small cell lung cancer or cancer that cannot be surgically removed. This type of cancer is known to spread rapidly to other areas of the body (metastatic). Rahika 150 mg Tablet circulates through the bloodstream and targets cancerous cells in the lungs and other parts of the body. It contains Capmatinib, which belongs to a class of medications called 'kinase inhibitors.' It blocks the action of an abnormal protein (the mesenchymal-epithelial transition [MET] gene) that helps cancer cells in the lungs grow and multiply. In this way, Rahika 150 mg Tablet slows or stops the growth and spread of cancer cells throughout the body.

Before starting treatment with Rahika 150 mg Tablet , inform your doctor if you are allergic to any of its ingredients or other medications. Rahika 150 mg Tablet may increase your sensitivity to sunlight, so it is important to limit exposure to sunlight and use sunscreen and protective clothing when going outdoors. Do not use Rahika 150 mg Tablet if you are pregnant or planning pregnancy, as it may harm an unborn baby. Be sure to use effective birth control during treatment and for at least one month after your last dose. Tell your doctor about your medical history, particularly if you have liver disease, lung problems, or pancreatitis (inflammation of the pancreas), before starting Rahika 150 mg Tablet .